|
| |
Genelabs TechnologiesGenelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate.
| Contact Details: |
| 505 Penobscot Drive |
| Redwood City |
| CA |
| 94063 |
| United States of America |
| Tel: | 650 369 9500 |
| Fax: | 650 368 0709 |
| Email: | info@genelabs.com |
| WWW: | www.genelabs.com/
|
|
Loading...
|
Recent Publications by Genelabs Technologies: |  |
Intramolecular transacylation: fragmentation of protonated molecules via ion-neutral complexes in mass spectrometry.
An intramolecular transacylation reaction was observed in the mass... | 14th August, 2009
| Drug Metabolism and Pharmacokinetics, Genelabs Technologies, Inc., 505
| Rapid Commun Mass Spectrom. 2009 Jul;23(13):1970-6.
DOI Direct Link |
NS5A--from obscurity to new target for HCV therapy.
The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is essential... | 27th September, 2008
| Genelabs Technologies, Inc., 505 Penobscot Drive, Redwood City, CA 94063,
| Recent Pat Antiinfect Drug Discov. 2008 Jun;3(2):77-92.
|
Synthesis and biological activity of 7-deaza-7-ethynyl-2'-deoxy-2'-fluoro-2'-C-methyladenosine and its 2'-C-methyl-ribo analogue.
In our search for improved therapeutic agents against HCV we synthesized... | 9th September, 2008
| Genelabs Technologies, Inc., 505 Penobscot Drive, Redwood City, CA 94063,
| Nucleic Acids Symp Ser (Oxf). 2008;(52):643-4.
DOI Direct Link |
Autoimmunity, dehydroepiandrosterone (DHEA), and stress.
With the urgent need for novel agents to combat emerging fungal resistance... | 24th September, 2004
| Genelabs Technologies, Inc., Redwood City, California 94063, USA.
| J Adolesc Health. 2002 Apr;30(4 Suppl):37-43.
|
A novel assay to determine the sequence preference and affinity of DNA minor groove binding compounds.
Sequence-specific binding in the minor groove of DNA by small molecules is... | 22nd January, 2004
| Genelabs Technologies, Inc., Redwood City, CA 94063, USA.
| Nucleic Acids Res. 2004 Jan 12;32(1):e8.
DOI Direct Link |
→View more Genelabs Technologies research publications. |
Press Releases on Genelabs Technologies:
|
 |
| Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions |
25th August, 2009 |
Adamas Pharmaceuticals, Inc. |
-- ADS-8703, a proprietary fixed-dose combination for the symptomatic
treatment of dementia.
About Mr. Coffee and Dr. Patick
Mr. Coffee brings more than 30 years sales, marketing and
|
| GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc. |
7th January, 2009 |
GlaxoSmithKline plc |
LONDON, Jan. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition
|
| GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc. |
30th December, 2008 |
GlaxoSmithKline plc |
LONDON, Dec. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that it has reduced the minimum tender condition and extended its previously announced tender offer to
|
| GlaxoSmithKline Further Extends Tender Offer to Acquire Genelabs Technologies, Inc. |
15th December, 2008 |
GlaxoSmithKline plc |
LONDON, Dec. 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that it has extended its previously announced tender offer to purchase all of the outstanding shares of
|
| GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc. |
8th December, 2008 |
GlaxoSmithKline |
LONDON, and PHILADELPHIA, Dec. 8 /PRNewswire-FirstCall/ -- GlaxoSmithKline
(LSE/NYSE: GSK) announced today that it has extended its previously announced
tender offer to purchase all of the
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 477 times since April 2007, the link to the organisation's website has been followed 90 times Recent Search Terms used to find this page: genelabs HCV NS5A | genelabsns5a | info on genelabs | ns5a-from obscurity to new target for hcv terapy recent pat antiinfec drug discovery | email address for Genelabs Technlogies | Recent Pat Antiinfect Drug Discov. 2008 Jun 3(2) 77-92. | small molecule companies in redwood city CA | genelabs technologies redwood city ca | genelabs | genelabs NS5A | . Search for more companies in Redwood City Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Genelabs Technologies |
